STELLA PHARMA
NEWS
May 23rd, 2025
Statistically Significant Difference in Results for Primary Endpoint of Clinical Trial for Recurrent High-Grade Meningioma – Presentation at the 2025 Annual Meeting of the American Society of Clinical Oncology (ASCO)
Stella Pharma is pleased to announce the results of the Phase II investigator-i……
April 15th, 2025
Phase I/II Clinical Trial in Japan for Thoracic Malignant Solid Tumors has started
Stella Pharma announces that it has started the first patient trial for the do……
April 9th, 2025
Presentation on the Clinical Trial for Recurrent High-Grade Meningioma at the 2025 Annual Meeting of the American Society of Clinical Oncology (ASCO)
At the 2025 Annual Meeting of the American Society of Clinical Oncology (ASCO),……
We are proud to announce that we will exhibit at the Osaka Healthcare Pavilion ……
